Business
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide ATLANTA, GA - April 14, 2026
About this update from Geovax Labs, Inc.
[{"type":"text","content":"Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide \nATLANTA, GA - April 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today highlighted the urgent challenges caused by the supply-constrained, global orthopoxvirus vaccine market and outlined the strategic positioning of its GEO-MVA vaccine candidate to address the limited supply and increasing global demand.\nA Procurement-Driven Market with Recurring Global Demand\nThe global market for vaccines targeting mpox and smallpox (orthopoxviruses) has evolved into a recurring, procurement-driven market supported by:\n National stockpile programs across the United States, Europe and allied countries\n Ongoing purchasing by global health organizations and regional agencies\n Outbreak-driven surge demand tied to periodic global transmission events\n \n Recent mpox outbreaks across multiple continents, including the emergence of more virulent strains, have reinforced the need for sustained vaccine supply beyond emergency response cycles.\nSingle-Supplier Market Structure and Limited Surge Capacity\nThe current global supply of MVA vaccines, the preferred vaccine for orthopoxvirus infections due to their recognized safety for use in vulnerable populations, is concentrated with a single commercial supplier.\nThis market structure has contributed to:\n Limited surge capacity during outbreaks\n Repeated depletion of government stockpiles\n Increased focus on supply chain resilience and diversification\n \n As a result, governments and public health agencies are increasingly prioritizing:\n Establishment of additional sources of MVA vaccine supply\n Expansion of domestic and allied manufacturing capacity\n Reduced dependence on single-source providers for critical countermeasures\n \n An Established Market Measured in Hundreds of Millions Annually\nPublic disclosures and procurement activity indicate that the mpox/smallpox vaccine market:\n Has generated hundreds of millions of dollars in annual procurement in recent years\n Includes multiyear purchasing frameworks and forward-looking supply agreements\n Is supported by both baseline stockpiling demand and outbreak-driven purchasing cycl...